4559:TYO
Zeria Pharmaceutical Co Ltd
2 292,00 ¥
arrow_upward
+0,97%(+22,00) 1 p
29. mai, 15:30:00 GMT +9 · JPY
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4559 põhistatistika genereerimine…
Ava
2 270 ¥
Kõrge
2 292 ¥
Madal
2 267 ¥
Turu kapit.
114,87 mld
Keskm. maht
94,27 tuh
Maht
150,00 tuh
Dividend
2,14%
Kvartaalne dividend
12 ¥
Dividendikuupäev
29. sept 2025
Hinna ja tulu suhe
11,95
52 näd kõrgeim
2 434 ¥
52 näd madalaim
1 878 ¥
Aktsiatulu
192 ¥
Käibivad aktsiad
50,11 mln
Töötajate arv
2 tuh
Ava
2 270 ¥
Kõrge
2 292 ¥
Madal
2 267 ¥
Turu kapit.
114,87 mld
Keskm. maht
94,27 tuh
Maht
150,00 tuh
Dividend
2,14%
Kvartaalne dividend
12 ¥
Dividendikuupäev
29. sept 2025
Hinna ja tulu suhe
11,95
52 näd kõrgeim
2 434 ¥
52 näd madalaim
1 878 ¥
Aktsiatulu
192 ¥
Käibivad aktsiad
50,11 mln
Töötajate arv
2 tuh
Uudised
Erinevatest veebiallikatest
Moomoo
·
10 minuti eest
Dow Jones Top Company Headlines at 3 PM ET: Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman | CVC ...
MarketBeat
·
37 minuti eest
Bank of America Issues Positive Forecast for NetApp (NASDAQ:NTAP) Stock Price
qz.com
·
46 minuti eest
Michael Reinking on S&P 500 climbing amid Iran uncertainty
MarketWatch
·
2 tunni eest
These S&P 500 stocks have soared the most during the AI-driven May rally
Profiil
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Teave üksuse Zeria Pharmaceutical Co Ltd kohta
AI genereeritud sisu võib sisaldada vigu. Lisateave